A novel germline hyperactivating JAK2 mutation L604F

Area of Science:

• Molecular Biology
• Hematology
• Genetics

Background:

• Somatic JAK2 mutations, particularly V617F, are the primary cause of polycythemia vera (PV).
• The V617F mutation enhances JAK2 dimer stability and kinase activity.
• Germline JAK2 mutations can modulate the effects of V617F but typically do not significantly alter JAK2 signaling alone.

Purpose of the Study:

• To investigate the functional consequences of an unusual germline JAK2 mutation, L604F, found in a young PV patient and her family.
• To compare the effects of L604F with the well-characterized V617F mutation on JAK2 signaling.
• To elucidate the mechanism by which L604F influences JAK2 dimer formation and activity.

Main Methods:

• Functional analysis of JAK2 L604F and V617F mutations in HEK293T cells expressing exogenous JAK2-GFP.
• CRISPR/Cas9-mediated modification of endogenous JAK2 in HeLa cells to assess mutation effects.
• Comparison of JAK2 kinase activity and protein levels in cells with different JAK2 mutations.

Main Results:

• Both JAK2 L604F and V617F mutations significantly increased constitutive JAK2 kinase activity in HEK293T cells.
• JAK2 L604F-induced hyperactivation was only partially inhibited by the F595 alanine substitution, unlike V617F.
• Endogenous JAK2 modifications in HeLa cells led to reduced total JAK2 protein levels.

Conclusions:

• The germline JAK2 L604F mutation contributes to JAK2 hyperactivation, potentially by increasing spontaneous dimer formation and stabilizing dimers.
• L604F may play a role in PV pathogenesis, possibly by modulating the effects of other JAK2 mutations like V617F.
• These findings expand our understanding of JAK2 mutations in PV and suggest L604F as a potential factor in disease development.